Last Updated: May 3, 2026

Litigation Details for Nokia Technologies Oy v. Amazon.com, Inc. (D. Del. 2023)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Nokia Technologies Oy v. Amazon.com, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Nokia Technologies Oy v. Amazon.com, Inc. | 1:23-cv-01236: Litigation Posture, Patent Scope, and Case-Impact Analysis

Last updated: April 25, 2026

What is the case and where does it sit on the litigation timeline?

Case: Nokia Technologies Oy v. Amazon.com, Inc.
Docket: 1:23-cv-01236
Court: United States District Court (district not specified in the available record)
Filing year: 2023
Case type: Patent infringement litigation (asserted against Amazon)

Only high-level procedural posture can be stated from the information provided: the matter is a 2023-filed federal case by Nokia Technologies Oy against Amazon.com, Inc., under docket 1:23-cv-01236. No additional record (e.g., complaints, claim charts, asserted patents list, scheduling orders, motions, claim construction outcomes, or trial dates) is present in the supplied input.

What patents and claims are at issue?

No asserted-patent list, claim numbers, or claim-construction outcomes are present in the supplied input. As a result, no accurate mapping of which Nokia patents target Amazon products or cloud services, which claim limitations drive infringement and validity arguments, or which claims were narrowed or construed can be produced.

What claims are likely the infringement focus against Amazon?

No product mapping, accused functionality, or claim chart content is present in the supplied input. Without the complaint’s allegations or amendment history, the infringement theory (system claims vs method claims; direct vs induced vs contributory) cannot be stated accurately.

How does Nokia typically structure these disputes (and what does that imply here)?

Nokia Technologies Oy’s patent enforcement in telecom and connectivity ecosystems commonly involves standards- and infrastructure-related IP and allegations framed around mobile networking, device-to-cloud connectivity, and related data flows. However, this is not case-specific and cannot be tied to 1:23-cv-01236 without the asserted patents and the pleadings.

What procedural milestones matter most for business and investment decisions?

For patent cases of this type, the most decision-relevant milestones usually include:

  1. Service of the complaint and early infringement contentions (or initial Rule 26 disclosures)
  2. Markman (claim construction) outcomes
  3. Daubert and summary-judgment motions tied to claim scope
  4. Validity defenses (anticipation/obviousness based on prior art) and indefiniteness/enablement
  5. Settlement pressure windows following claim construction and partial summary judgment

None of these milestones’ dates, rulings, or outcomes are provided in the supplied input, so this analysis cannot be concretely tied to the case record.

What is the current litigation risk profile for Amazon under this docket?

A risk profile requires at minimum:

  • asserted patent count and technology,
  • claim scope as construed,
  • identified accused products and technical diagrams or service descriptions,
  • damages theory and royalty base,
  • and any dispositive rulings.

Those inputs are not in the provided material. The only accurate statement is that the case is pending (filed in 2023) and alleges patent infringement by Amazon.com, Inc. under docket 1:23-cv-01236.

What is the likely damages exposure framework?

Damages analysis depends on:

  • the asserted patents’ eligibility for damages,
  • claim coverage and how many claims survive,
  • the royalty rate framework (e.g., comparable licenses, Georgia-Pacific factors, or other accepted approaches),
  • and the relevant time period tied to notice and marking.

No damages content is present in the supplied input, so a quantified exposure statement cannot be produced without inventing specifics.

How should Nokia’s legal posture be evaluated from an IP-commercial perspective?

To evaluate Nokia’s posture in a case like this, the record must show:

  • whether Nokia sought preliminary relief (rare, but material),
  • whether Nokia amended infringement contentions to strengthen claim coverage,
  • whether Nokia’s asserted patents map cleanly to specific Amazon offerings,
  • and whether Nokia attacked Amazon’s non-infringement defenses in dispositive motion practice.

No such record elements are available in the supplied input.

What are the key decision points for a counterparty (licensing vs litigating)?

With the complete case docket and filings, the decision points typically narrow to:

  • whether claim construction increases or reduces literal infringement,
  • whether validity motions eliminate asserted patents,
  • whether the court narrows claim scope in ways that break the infringement chain,
  • and the strength of damages evidence.

Those are not available in the supplied input.

Bottom line: what can be concluded from the provided information?

From the information provided, the case fact pattern is limited to:

  • Parties: Nokia Technologies Oy (plaintiff) vs Amazon.com, Inc. (defendant)
  • Federal docket: 1:23-cv-01236
  • Year filed: 2023
  • Nature: patent infringement litigation No additional case-specific findings can be stated without asserting facts not supplied.

Key Takeaways

  • Nokia Technologies Oy v. Amazon.com, Inc. is a 2023 federal patent infringement case under docket 1:23-cv-01236.
  • The provided input does not include the asserted patents, accused products, infringement theories, claim constructions, motion outcomes, or damages framework; case-specific litigation analysis cannot be completed on the record given.
  • Any business impact assessment (validity risk, infringement likelihood, and damages exposure) depends on those missing case-document inputs.

FAQs

  1. What court is 1:23-cv-01236 in?
    The supplied input does not specify the district.

  2. Which Nokia patents are asserted in this docket?
    The asserted patent list is not provided in the supplied input.

  3. What Amazon products or services are accused?
    The accused functionality is not provided in the supplied input.

  4. Has there been claim construction (Markman) in this case?
    The supplied input does not include any claim construction rulings.

  5. Is the case at the motion stage, trial stage, or appeal stage?
    The supplied input provides no procedural-stage details beyond filing in 2023.


References

[1] Nokia Technologies Oy v. Amazon.com, Inc., 1:23-cv-01236 (case docket information as provided in the prompt).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.